Sean Bohen hauls in a multimillion-dollar windfall as his newly adopted biotech bags a $209M-plus IPO
Sean Bohen’s IPO for Olema Oncology priced at $19 a share overnight, going over the top of the range and giving him an initial multimillion-dollar stake in the biotech as it ventures out into its first day of trading on Thursday.
In their revised S-1 out a few days ago, the company did a reverse split on his shares, leaving Bohen with an option on 1,110,896 shares — about 3% of the company — at the reconfigured exercise price of $4.82. Those options can be exercised within the next 40 days.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,300+ biopharma pros reading Endpoints daily — and it's free.